Scleral fixation of fluocinolone acetonide implant [PDF]
American Journal of Ophthalmology Case Reports, 2020 Purpose: To report on the technique of scleral fixation of fluocinolone acetonide (FAc) implant in 2 eyes with recalcitrant diabetic macular edema (DME). Observations: Two eyes of 2 patients with persistent DME, partially responsive to anti-VEGF therapy,
Homayoun Tabandeh, Kourous Rezaei
doaj +4 more sources
Fluocinolone Acetonide Implant Removal From the Vitreous Cavity. [PDF]
J Vitreoretin Dis, 2023 Purpose: To describe a technique for fluocinolone acetonide implant removal from the vitreous cavity. Methods: A case report and review of surgical methods were performed. Results: The technique to remove a fluocinolone acetonide implant from the vitreous cavity was safe and effective. The vitreous cutter was used to align the implant coaxially with a
Valikodath N, Vajzovic L.
europepmc +3 more sources
Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema: a systematic review with meta-analysis of real-world experience [PDF]
Scientific Reports, 2021 We conducted a meta-analysis of real-world studies on the 0.19 mg Fluocinolone Acetonide (FAc) intravitreal implant for chronic diabetic macular oedema (DMO), comparing these findings with the Fluocinolone Acetonide for Diabetic Macular Edema (FAME ...
Matteo Fallico +14 more
doaj +2 more sources
Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis. [PDF]
J Clin Med, 2021 The efficacy of the 0.19-mg fluocinolone acetonide (FAc) intravitreal implant (ILUVIEN) in the treatment of non-infectious uveitic macular edema (UME) was assessed on twenty-six patients (34 eyes) with non-infectious UME between 2013 and 2020, in a mean follow-up of 18 ± 19.3 (mean ± SD) months. Macular edema was resolved in 24 (70.6%) cases.
Hikal M +5 more
europepmc +4 more sources
Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries. [PDF]
Ophthalmol Ther, 2022 none14siIntroduction: The 0.19 mg fluocinolone acetonide (FAc) intravitreal implant delivers a continuous intravitreal corticosteroid dose for the treatment of refractory diabetic macular oedema (DMO). The aim of this study was to assess the impact of an
Lebrize S +13 more
europepmc +4 more sources
Radiation-induced maculopathy and fluocinolone acetonide implant. [PDF]
Graefes Arch Clin Exp OphthalmolAbstract Purpose This study evaluates the effectiveness of fluocinolone acetonide (FAc) implants in managing radiation maculopathy, a complication of ocular irradiation. The primary outcomes were the change in best-corrected visual acuity (BCVA) and central foveal thickness (CFT), and the impact on therapeutic burden ...
Fricker J +8 more
europepmc +3 more sources
Intravitreal Fluocinolone Acetonide Implant (ILUVIEN<sup>®</sup>) for the Treatment of Retinal Conditions. A Review of Clinical Studies. [PDF]
Drug Des Devel Ther, 2023 Fluocinolone acetonide (FAc) intravitreal implant (Iluvien®) is a corticosteroid implant indicated for the treatment of diabetic macular oedema (DMO) in patients who have previously received conventional treatment without good response, non– infectious ...
Mushtaq Y +5 more
europepmc +3 more sources
Recurrent Diabetic Macular Edema: What to Do [PDF]
Case Reports in Ophthalmology, 2017 Diabetic macular edema (DME) is a leading cause of blindness in the working population. Herein, we report the case of a patient with recurrent DME for about 6 years, uncontrolled by several medical and surgical treatments, that was successfully treated ...
Rita Santos Gonçalves +2 more
doaj +3 more sources
Fluocinolone Acetonide Implant Injected 1 Month after Dexamethasone Implant for Diabetic Macular Oedema: the ILUVI1MOIS Study [PDF]
Ophthalmology and Therapy, 2023 Introduction The aim of this study was to assess the efficacy and safety of fluocinolone acetonide implant (FAci) injected 1 month after the last dexamethasone intravitreal implant (DEXi) in chronic diabetic macular oedema (DME) patients.
Nicolas Rousseau +12 more
doaj +2 more sources
Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review [PDF]
Journal of International Medical Research, 2019 Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti ...
Horace Massa +5 more
doaj +2 more sources